1. Medtech Insight
  2. >>Business
  3. >>Strategy

People Briefs: GI Dynamics CEO; Allergan CFO; HeartFlow Changes

New CEO for GI Dynamics. Allergan names Jim Hindman CFO. HeartFlow makes executive suite changes; Biogen Idec appoints new executive VP.

Device industry veteran Michael D. Dale will be the next CEO of EndoBarrier gastrointestinal liner device developer GI Dynamics Inc., effective Sept. 18. Dale will replace Stuart Randle, who has led the Lexington, Massachusetts-based startup since 2004, the company announced Aug. 28. Dale was most recently president and CEO of Helical Solutions, a venture capital-funded business focused on atrial fibrillation. Previously, he was chairman, president and CEO of publicly traded heart valve firm ATS Medical until it was acquired by Medtronic in 2010. (See Also see "Medtronic Shores Up Tissue Valve Portfolio With ATS Medical Acquisition" - Medtech Insight, 3 May, 2010..) He has also served executive roles at Endocardial Solutions, Cyberonics, St. Jude Medical and Edwards Lifesciences.

Under Randle’s tenure, GI Dynamics launched EndoBarrier for type 2 diabetes and obesity in Europe in 2010 and it successfully completed in an initial public offering on the Australian stock...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

More from Business

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.